184 related articles for article (PubMed ID: 20177129)
1. Seeing injectable ms therapies differently: they are more similar than different.
Johnson KP; Fox RJ; Arnold DL
Neurology; 2010 Feb; 74(8):702. PubMed ID: 20177129
[No Abstract] [Full Text] [Related]
2. Seeing injectable MS therapies differently: they are more similar than different.
Fox RJ; Arnold DL
Neurology; 2009 Jun; 72(23):1972-3. PubMed ID: 19439722
[No Abstract] [Full Text] [Related]
3. [Diagnostics and drug therapy of multiple sclerosis].
Suomen Neurologinen Yhdistys ry
Duodecim; 2002; 118(13):1411-23. PubMed ID: 12239889
[No Abstract] [Full Text] [Related]
4. [Drug therapy of multiple sclerosis].
Kinnunen E
Duodecim; 1999; 115(4):403-7. PubMed ID: 11830889
[No Abstract] [Full Text] [Related]
5. Impact of disease-modifying therapies on brain and spinal cord atrophy in multiple sclerosis.
Rudick RA
J Neuroimaging; 2004 Jul; 14(3 Suppl):54S-64S. PubMed ID: 15228760
[TBL] [Abstract][Full Text] [Related]
6. Current disease-modifying therapies in multiple sclerosis.
Kieseier BC; Hartung HP
Semin Neurol; 2003 Jun; 23(2):133-46. PubMed ID: 12894379
[TBL] [Abstract][Full Text] [Related]
7. [Early immunomodulatory treatment of multiple sclerosis: pros and cons].
Wender M
Neurol Neurochir Pol; 2003; 37(4):777-82. PubMed ID: 14746238
[TBL] [Abstract][Full Text] [Related]
8. Glatiramer acetate (Copaxone).
Francis DA
Int J Clin Pract; 2001; 55(6):394-8. PubMed ID: 11501229
[TBL] [Abstract][Full Text] [Related]
9. The effect of glatiramer acetate treatment on pre-existing headaches in patients with MS.
Pöllmann W; Erasmus LP; Feneberg W; Straube A
Neurology; 2006 Jan; 66(2):275-7. PubMed ID: 16434675
[TBL] [Abstract][Full Text] [Related]
10. New treatments for multiple sclerosis.
Hutchinson M
Ir Med J; 1996; 89(2):44. PubMed ID: 8682623
[No Abstract] [Full Text] [Related]
11. Biogen wins Euro MS approval, but loses patents.
Brower V
Nat Biotechnol; 1997 May; 15(5):410. PubMed ID: 9131611
[No Abstract] [Full Text] [Related]
12. [Multiple sclerosis].
Itoyama Y
No To Shinkei; 2000 Dec; 52(12):1051-5. PubMed ID: 11193536
[No Abstract] [Full Text] [Related]
13. [Current concepts on the use of some immunomodulatory drugs in the treatment of multiple sclerosis].
Correale J; Cristiano E
Medicina (B Aires); 2001; 61(4):470-80. PubMed ID: 11563177
[TBL] [Abstract][Full Text] [Related]
14. Update on MS treatment.
Ryan M
J Am Pharm Assoc (Wash); 1996 Jul; NS36(7):419-20. PubMed ID: 8840740
[No Abstract] [Full Text] [Related]
15. [Clinical surveillance of patients with multiple sclerosis].
Cazzato G; Zorzon M
Recenti Prog Med; 2003 Apr; 94(4):173-6. PubMed ID: 12677789
[TBL] [Abstract][Full Text] [Related]
16. 'Time is brain' also in multiple sclerosis.
Freedman MS
Mult Scler; 2009 Oct; 15(10):1133-4. PubMed ID: 19808740
[No Abstract] [Full Text] [Related]
17. [New therapeutic methods in the treatment of multiple sclerosis].
Nervenarzt; 1996 Nov; 67(11 Suppl Neue Ther):1-12. PubMed ID: 9402424
[No Abstract] [Full Text] [Related]
18. Glatiramer and suspected multiple sclerosis. No proven advantage.
Prescrire Int; 2010 Aug; 19(108):160. PubMed ID: 20941852
[No Abstract] [Full Text] [Related]
19. [Rationale for an early treatment of multiple sclerosis].
Comi G; Martino G
Rev Neurol; 2000 Jun 16-30; 30(12):1265-8. PubMed ID: 10935262
[TBL] [Abstract][Full Text] [Related]
20. Disease-modifying drugs for the early treatment of multiple sclerosis.
Flachenecker P
Expert Rev Neurother; 2004 May; 4(3):455-63. PubMed ID: 15853542
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
